Jump to content

Turkovac

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Renamed user 864c737a9ba5264134504237052363d9 (talk | contribs) at 06:59, 26 September 2021 (→‎References: removed stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

TURKOVAC
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesERUCOV-VAC
Routes of
administration
Intramuscular

TURKOVAC[1] (pronunciation: [[Help:IPA/Turkish|['tɜ:rkəvæk]]]) (temporarily named as ERUCOV-VAC[2]) is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.

Clinical trials

In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[3]

In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[4]

In June, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[5]

References

  1. ^ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
  2. ^ "Domestic COVID-19 jab Turkovac begins Phase 3 trials in Turkey". Daily Sabah. 22 June 2021. Retrieved 23 June 2021.
  3. ^ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 " at ClinicalTrials.gov
  5. ^ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.